Devroe Eric 4

What Happened

• Eric Devroe, Chief Operating Officer of Acrivon Therapeutics (ACRV), was granted a derivative award on March 1, 2026 covering 186,728 shares. The grant shows an acquisition price of $0.00 (i.e., an awarded option/award rather than an open‑market purchase). This filing reports a compensatory grant rather than a sale or cash purchase.

Key Details

• Transaction date: 2026-03-01; Form 4 filed: 2026-03-03 (timely).
• Type/code: Grant/Award (transaction code A); recorded as a derivative security (option).
• Shares involved: 186,728 shares; acquisition price reported $0.00.
• Vesting (footnote): 25% vests on March 1, 2027; remaining shares vest in 36 substantially equal monthly installments thereafter, subject to continuous service.
• Shares owned after transaction: Not disclosed on the provided summary of this filing.
• No 10b5-1 plan, tax-withholding sale, or immediate cashless exercise indicated.

Context

• This is a compensation award (stock option) intended to vest over time to retain/aligned interests; it does not represent an immediate market purchase or sale. Such grants are common for executives and signal long‑term incentive rather than short‑term trading.